Pfizer (PFE) Long-Term Debt Repayments (2009 - 2025)

Pfizer (PFE) has 17 years of Long-Term Debt Repayments data on file, last reported at $3.0 billion in Q4 2025.

• Long-Term Debt Repayments for Q4 2025 came in at $3.0 billion, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $6.8 billion (changed N/A YoY), and the FY2025 annual result was $6.8 billion, up 200.31% from the prior year.
• Long-Term Debt Repayments eased to $3.0 billion in Q4 2025 per PFE's latest filing, from $3.8 billion in the prior quarter.
• Over five years, Long-Term Debt Repayments peaked at $3.8 billion in Q2 2025 and troughed at $269.0 million in Q2 2023.
• A 5-year average of $1.6 billion and a median of $1.3 billion in 2023 frame the typical range for Long-Term Debt Repayments.
• The sharpest annual moves came in 2023 and 2024: Long-Term Debt Repayments tumbled 83.28% in 2023, then jumped 364.68% in 2024.
• A 5-year view of Long-Term Debt Repayments shows it stood at $1.0 billion in 2021, then surged by 60.74% to $1.6 billion in 2022, then fell by 19.2% to $1.3 billion in 2023, then surged by 73.08% to $2.2 billion in 2024, then soared by 33.64% to $3.0 billion in 2025.
• Business Quant data shows PFE's Long-Term Debt Repayments at $3.0 billion in Q4 2025, $3.8 billion in Q2 2025, and $2.2 billion in Q3 2024.